Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03233347 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Results posted: Sep 15, 2026 Show 7 more changesShow less
    • Study completion pushed from Jul 8, 2026 to Jul 8, 2027
    • Enrollment target: estimated 82 to confirmed 83
    • Eligibility criteria shortened, about 18 words
    • Secondary endpoints: 11 to 10
    • Primary endpoint revised
    • Study description revised
    • Site details revised at 3 of 9 sites
  2. Primary completion date: Jul 1, 2022 to Jul 1, 2025
    • Study completion date: Jul 8, 2025 to Jul 8, 2026
    v21
  3. Primary completion date changed from estimate of Aug 1, 2024 to Jul 1, 2022
    • Study completion date: Aug 7, 2024 to Jul 8, 2025
    v20
  4. Primary completion date: Aug 1, 2023 to Aug 1, 2024v19
  5. Re-verified, no change to tracked fieldsv18
Show 16 earlier versionsHide 16 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 13 to 9
    v17
  2. Re-verified, no change to tracked fieldsv16
  3. Site details revised at 1 of 13 sitesv15
  4. Study sites: 9 to 13v14 Show 5 more changesShow less
    • Interventions: Brentuximab Vedotin (Drug), Dacarbazine (Drug), Doxorubicin Hydrochloride (Drug), Laboratory Biomarker Analysis (Other), Nivolumab… to Brentuximab Vedotin (Drug), Dacarbazine (Drug), Doxorubicin (Drug), Laboratory Biomarker Analysis (Other), Nivolumab (Biological)…
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: 13 to 11
    • Study description expanded, about 58 words
    • Study title shortened, about 1 word
  5. Study sites: 11 to 9v13
  6. Re-verified, no change to tracked fieldsv12
  7. Eligibility criteria revised
    • Study description revised
    • Study sites revised (11)
    v11
  8. Study sites: 10 to 11v10
  9. Site details revised at 1 of 10 sitesv9
  10. Site details revised at 1 of 10 sitesv8
  11. Site details revised at 1 of 10 sitesv7
  12. Site details revised at 1 of 10 sitesv6
  13. Site details revised at 1 of 10 sitesv5
  14. Site details revised at 1 of 10 sitesv4
  15. Trial status: Not Yet Recruiting to Recruitingv3 Show 6 more changesShow less
    • Enrollment target: 85 to 82
    • Study sites: 6 to 10
    • Study completion date: Aug 1, 2025 to Aug 7, 2024
    • Start date changed from estimate of Feb 18, 2018 to Oct 13, 2017
    • Eligibility criteria expanded, about 57 words
    • Secondary endpoints reordered
  16. Start date: Aug 18, 2017 to Feb 18, 2018v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial evaluates how well AVD (doxorubicin, vinblastine, dacarbazine) in combination with brentuximab vedotin and nivolumab work in treating patients with stage I-II Hodgkin lymphoma. Drugs used in the chemotherapy, such as doxorubicin, vinblastine, dacarbazine, and brentuximab vedotin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, and/or by stopping them from spreading. Targeted agent, such as nivolumab, may interfere with the ability of cancer cells to grow and spread by enhancing the immune system. Giving doxorubicin, vinblastine, dacarbazine, brentuximab vedotin, and nivolumab may improve survival of patients with stage I-II Hodgkin lymphoma.
Trial Details
NCT Number NCT03233347
Lead Sponsor Academic and Community Cancer Research United
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Enrollment 83 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov